Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)

SHE:300519 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	379.07	311.84	503.42	543.95	622.03	593.67
Trading Asset Securities	370	400	185	155	115	125
Cash & Short-Term Investments	749.07	711.84	688.42	698.95	737.03	718.67
Cash Growth	8.46%	3.40%	-1.51%	-5.17%	2.56%	6.18%
Accounts Receivable	16.53	11.11	12.58	10.74	25.48	17.51
Other Receivables	0.07	0.16	0.04	0.18	0.04	0.16
Receivables	16.6	11.27	12.62	10.92	25.52	17.67
Inventory	35.21	43.27	69.34	71.42	46.15	46.76
Other Current Assets	2.56	0.97	4.34	3.89	3.57	2.82
Total Current Assets	803.44	767.34	774.71	785.17	812.26	785.92
Property, Plant & Equipment	83.31	92.96	105.52	115.47	114.88	114.68
Long-Term Investments	15.73	21.5	21.42	21.4	20.37	20.54
Other Intangible Assets	7.37	7.59	7.88	8.17	9.28	10.41
Long-Term Deferred Tax Assets	-	0.03	0.25	0.2	0.93	0.82
Other Long-Term Assets	-	-	-	-	0.03	0.04
Total Assets	909.84	889.42	909.78	930.41	957.76	932.4

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	37.13	28.58	56.01	63.88	56.75	56.11
Accrued Expenses	0.76	12.86	11.29	11.14	17.82	12.89
Current Income Taxes Payable	9.1	1.96	2.38	0.76	12.82	5.34
Current Unearned Revenue	0.43	0.29	0.07	0.16	0.14	0.09
Other Current Liabilities	1.41	1.02	0.86	1.15	0.84	0.79
Total Current Liabilities	48.83	44.71	70.61	77.08	88.37	75.22
Long-Term Unearned Revenue	4.58	5.53	6.28	6.84	7.71	8.15
Long-Term Deferred Tax Liabilities	0.01	-	-	-	0.43	0.45
Other Long-Term Liabilities	2.36	2.36	2.36	2.36	2.36	2.36
Total Liabilities	55.78	52.6	79.25	86.29	98.86	86.19

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	160	160	160	160	160	160
Additional Paid-In Capital	161.29	161.29	161.29	161.29	161.29	161.29
Retained Earnings	529.62	512.15	505.94	519.55	535.19	522.37
Comprehensive Income & Other	3.15	3.37	3.31	3.29	2.42	2.56
Shareholders' Equity	854.06	836.81	830.53	844.12	858.89	846.22
Total Liabilities & Equity	909.84	889.42	909.78	930.41	957.76	932.4

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Net Cash (Debt)	749.07	711.84	688.42	698.95	737.03	718.67
Net Cash Growth	8.46%	3.40%	-1.51%	-5.17%	2.56%	6.18%
Net Cash Per Share	4.74	4.46	4.24	4.34	4.61	4.46
Filing Date Shares Outstanding	163.05	160	160	160	160	160
Total Common Shares Outstanding	163.05	160	160	160	160	160
Working Capital	754.61	722.63	704.11	708.09	723.9	710.69
Book Value Per Share	5.24	5.23	5.19	5.28	5.37	5.29
Tangible Book Value	846.69	829.23	822.66	835.95	849.61	835.8
Tangible Book Value Per Share	5.19	5.18	5.14	5.22	5.31	5.22
Buildings	-	116.99	116.99	116.47	112.48	95.23
Machinery	-	134.44	133.98	120.9	124.97	120.21
Construction In Progress	-	-	-	11	1.95	11.35

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error